Clinical trial
Therapy of HES, PV, Atypical Chronic Myelocytic Leukemia (CML) or Chronic…
NCT00038675 · M.D. Anderson Cancer Center, Other · Completed
Key facts
| NCT number | NCT00038675 |
|---|---|
| Title | Therapy of HES, PV, Atypical Chronic Myelocytic Leukemia (CML) or Chronic Myelomonocytic Leukemia (CMML), and Mastocytosis With Imatinib Mesylate |
| Official title | Therapy of Hypereosinophilic Syndrome, Polycythemia Vera, Atypical CML or CMML With Platelet Derived Growth Factor (PDGF-R) Fusion Genes, or Mastocytosis With Imatinib Mesylate (STI571) |
| Lead sponsor | M.D. Anderson Cancer Center, Other |
| Collaborators | Novartis Pharmaceuticals Industry |
| Status | Completed |
| Study type | Interventional |
| Conditions | Chronic Myelomonocytic Leukemia, Chronic Myeloid Leukemia, Polycythemia Vera, Hypereosinophilic Syndrome, Mastocytosis |
| Intervention type | Drug |
| Interventions | Imatinib Mesylate (Gleevec) |
| Enrollment | 125 |
| Start date | Jun 1, 2001 |
| Primary completion | Nov 1, 2013 |
| Completion | Nov 1, 2013 |
| First posted | Jun 5, 2002 |
| Last update posted | Jan 4, 2022 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: